Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia

References

• BoekholdtSMArsenaultBJMoraSAssociation of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysisJAMA2012307121302130922453571
   PubMed Web of Science ®Google Scholar
• MillerMStoneNJBallantyneCAmerican Heart Association Clinical Lipidology, thrombosis, and prevention committee of the council on nutrition, physical activity, and metabolism; council on arteriosclerosis, thrombosis and vascular biology; council on cardiovascular nursing; council on the kidney in cardiovascular disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart AssociationCirculation2011123202292233321502576
   PubMed Web of Science ®Google Scholar
• MakiKCGalantRDavidsonMHNon-high-density lipoprotein cholesterol: the forgotten therapeutic targetAm J Cardiol2005969A59K64K
   PubMed Web of Science ®Google Scholar
• JonesPHNairRThakkerKMPrevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysisJ Am Heart Assoc201216e00180023316314
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary prevention study groupN Engl J Med199533320130113077566020
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention StudyJAMA199827920161516229613910
   PubMed Web of Science ®Google Scholar
• NakamuraHArakawaKItakuraHMEGA Study GroupPrimary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trialLancet200636895421155116317011942
   PubMed Web of Science ®Google Scholar
• SeverPSDahlöfBPoulterNRASCOT InvestigatorsPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAJUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• No authors listedRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934138313897968073
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGEzekowitzMDMyocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study InvestigatorsEffects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trialJAMA2001285131711171811277825
   PubMed Web of Science ®Google Scholar
• No authors listedPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupN Engl J Med199833919134913579841303
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJIncremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study GroupHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA2005294192437244516287954
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHPravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 InvestigatorsIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350151495150415007110
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDTreating to New Targets (TNT) InvestigatorsIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med2005352141425143515755765
   PubMed Web of Science ®Google Scholar
• NordestgaardBGBennMSchnohrPTybjaerg-HansenANonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and womenJAMA2007298329930817635890
   PubMed Web of Science ®Google Scholar
• SarwarNDaneshJEiriksdottirGTriglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studiesCirculation2007115445045817190864
   PubMed Web of Science ®Google Scholar
• HokansonJEAustinMAPlasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studiesJ Cardiovasc Risk1996322132198836866
   PubMedGoogle Scholar
• NichollsSJBrandrup-WognsenGPalmerMBarterPJMeta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)Am J Cardiol20101051697620102893
   PubMed Web of Science ®Google Scholar
• LempGFVander ZwaagRHughesJPAssociation between the severity of diabetes mellitus and coronary arterial atherosclerosisAm J Cardiol19876013101510193314456
   PubMed Web of Science ®Google Scholar
• HaffnerSMLehtoSRönnemaaTPyöräläKLaaksoMMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med199833942292349673301
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNCARDS InvestigatorsPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• LeySHHarrisSBConnellyPWUtility of non-high-density lipoprotein cholesterol in assessing incident type 2 diabetes riskDiabetes Obes Metab201214982182522510237
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS)XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjectsDiabet Med19941165345447955969
   PubMed Web of Science ®Google Scholar
• SoranHSchofieldJDAdamSDurringtonPNDiabetic dyslipidaemiaCurr Opin Lipidol201627431332227213628
   PubMed Web of Science ®Google Scholar
• ChahilTJGinsbergHNDiabetic dyslipidemiaEndocrinol Metab Clin North Am2006353491510viiviii16959582
   PubMed Web of Science ®Google Scholar
• BarterPJBrandrup-WognsenGPalmerMKNichollsSJEffect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER DatabaseJ Lipid Res20105161546155319965573
   PubMed Web of Science ®Google Scholar
• HasvoldPThuressonMSundströmJAssociation between paradoxical HDL cholesterol decrease and risk of major adverse cardiovascular events in patients initiated on statin treatment in a primary care settingClin Drug Investig2016363225233
   PubMed Web of Science ®Google Scholar
• FrickMHEloOHaapaKHelsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart diseaseN Engl J Med198731720123712453313041
   PubMed Web of Science ®Google Scholar
• Bezafibrate infarction prevention (BIP) studySecondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery diseaseCirculation20001021212710880410
   PubMed Web of Science ®Google Scholar
• RobinsSJCollinsDWittesJTVA-HIT Study GroupVeterans affairs high-density lipoprotein intervention trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trialJAMA2001285121585159111268266
   PubMed Web of Science ®Google Scholar
• ScottRO’BrienRFulcherGFenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study InvestigatorsEffects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowering in diabetes (FIELD) studyDiabetes Care200932349349818984774
   PubMed Web of Science ®Google Scholar
• GinsbergHNElamMBLovatoLCThe ACCORD Study GroupEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• BodenWEProbstfieldJLAndersonTAIM-HIGH InvestigatorsNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar
• GuytonJRSleeAEAndersonTRelationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)J Am Coll Cardiol201362171580158423916935
   PubMed Web of Science ®Google Scholar
• TirkkonenTRyynänenAVahlbergTFrequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database studyDrug Saf200831323124018302447
   PubMed Web of Science ®Google Scholar
• LawsonLDHughesBGHuman absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl estersBiochem Biophys Res Commun198815213283353358766
   PubMed Web of Science ®Google Scholar
• LawsonLDHughesBGAbsorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat mealBiochem Biophys Res Commun198815629609632847723
   PubMed Web of Science ®Google Scholar
• BeckermannBBenekeMSeitzIComparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteersArzneimittelforschung19904067007042144420
   PubMed Web of Science ®Google Scholar
• DavidsonMHJohnsonJRooneyMWKyleMLKlingDFA novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacoki-netic single-dose evaluation) studyJ Clin Lipidol20126657358423312053
   PubMed Web of Science ®Google Scholar
• OffmanEMarencoTFerberSSteady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II studyVasc Health Risk Manag2013956357324124374
   PubMedGoogle Scholar
• PiepoliMFHoesAWAgewallS2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR)Eur Heart J201637292315238127222591
   PubMed Web of Science ®Google Scholar
• KasteleinJJMakiKCSusekovAOmega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trialJ Clin Lipidol2014819410624528690
   PubMed Web of Science ®Google Scholar
• Epanova® (omega-3 carboxylic acids) [prescribing information]New JerseyOmthera Pharmaceuticals, Inc2015
   Google Scholar
• PischonTGirmanCJSacksFMRifaiNStampferMJRimmEBNon-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in menCirculation2005112223375338316316964
   PubMed Web of Science ®Google Scholar
• MoriTABurkeVPuddeyIBWattsGFO’NealDNBestJDBeilinLJPurified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic menAm J Clin Nutr20007151085109410799369
   PubMed Web of Science ®Google Scholar
• Leigh-FirbankECMinihaneAMLeakeDSEicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responsesBr J Nutr200287543544512010583
   PubMed Web of Science ®Google Scholar
• KelleyDSSiegelDVemuriMMackeyBEDocosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic menAm J Clin Nutr200786232433317684201
   PubMed Web of Science ®Google Scholar
• MakiKCVan ElswykMEMcCarthyDLipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterolJ Am Coll Nutr200524318919915930485
   PubMed Web of Science ®Google Scholar
• BaysHEBallantyneCMBraeckmanRAStirtanWGSoniPNIcosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studiesAm J Cardiovasc Drugs2013131374623325450
   PubMed Web of Science ®Google Scholar
• HarrisWSMillerMTigheAPDavidsonMHSchaeferEJOmega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectivesAtherosclerosis20081971122418160071
   PubMed Web of Science ®Google Scholar
• DavidsonMHMechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acidsAm J Cardiol2006984A27i33i
   PubMed Web of Science ®Google Scholar
• DavidsonMHSteinEABaysHECOMBination of prescription Omega-3 with Simvastatin (COMBOS) InvestigatorsEfficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled studyClin Ther20072971354136717825687
   PubMed Web of Science ®Google Scholar
• MakiKCOrloffDGNichollsSJA highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)Clin Ther201335914001411e1e323998969
   PubMed Web of Science ®Google Scholar
• NakamuraNHamazakiTJokajiHMinamiSKobayashiMEffect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemiaInt J Clin Lab Res19982831921959801932
   PubMedGoogle Scholar
• DunbarRLNichollsSJMakiKCEffects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trialLipids Health Dis2015149826328624
   PubMed Web of Science ®Google Scholar
• DavidsonMHRooneyMWDruckerJEugene GriffinHOosmanSBeckertMLCP-AtorFen InvestigatorsEfficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group studyClin Ther200931122824283820110022
   PubMed Web of Science ®Google Scholar
• YokoyamaMOrigasaHMatsuzakiMJapan EPA Lipid Intervention Study (JELIS) InvestigatorsEffects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysisLancet200736995671090109817398308
   PubMed Web of Science ®Google Scholar
• BruckertEHayemGDejagerSYauCBégaudBMild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO studyCardiovasc Drugs Ther200519640341416453090
   PubMed Web of Science ®Google Scholar
• BraeckmanRAStirtanWGSoniPNEffect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatinClin Drug Investig20153514551
   PubMed Web of Science ®Google Scholar
• McKenneyJMSwearingenDDi SpiritoMStudy of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl estersJ Clin Pharmacol200646778579116809804
   PubMed Web of Science ®Google Scholar
• GosaiPLiuJDoyleRTJohnsonJCarterRSicaDMcKenneyJMEffect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adultsExpert Opin Pharmacother20089172947295319006471
   PubMed Web of Science ®Google Scholar
• Di SpiritoMMorelliGDoyleRTJohnsonJMcKenneyJEffect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adultsExpert Opin Pharmacother20089172939294519006470
   PubMed Web of Science ®Google Scholar